What question did this study set out to answer?

The study aims to compare the tolerance and efficacy of S-ketamine and racemic ketamine in surgical patients, focusing on hallucination occurrence.

May 7, 2026Open Access

Tolerability and efficacy profile of S-ketamine compared with racemic ketamine in surgical patients, a prospective observational before-and-after study in the perioperative setting

Key Points

The study aims to compare the tolerance and efficacy of S-ketamine and racemic ketamine in surgical patients, focusing on hallucination occurrence.
Prospective observational, before-and-after design
Conducted in four hospitals of the APHP Sorbonne Universite consortium from February to March 2024
Patients requiring anesthesia and receiving ketamine were included, with specific data recorded postoperatively.
Patients receiving racemic ketamine had a higher hallucination occurrence (1.4% vs 0%), P=0.04
Racemic ketamine patients received more morphine (10 mg vs 8 mg), P=0.02
Length of stay in PACU was similar for both groups, P=0.70.

Abstract

Background: While the S-enantiomer of Ketamine (S-Ketamine) is described to be more potent than the racemic form (Ra-Ketamine), with a shorter half-life and almost no side effects, both forms have never been compared in real life. This before-after observational study leverages an institutional switch across multiple hospitals from Ra- to S-Ketamine to compare their efficacy and tolerance profile. The primary aim was to assess the occurrence of hallucination in patients receiving racemic Ketamine compared with S-Ketamine, as a proxy for ketamine's tolerance, as it is the most specific adverse effect. Methods: This is a prospective, observational, before-aafter, multicentre study conducted in the four centres of the APHP Sorbonne Universite hospitals consortium (GHU Sorbonne Universite), Paris, from 19 February to 22 March 2024. All patients requiring anaesthesia for any type of surgery and receiving Ketamine during the study period were included. Exclusion criteria included persistent sedation after surgery. Hallucinations, PACU length of stay, analgesic strategies, and postoperative adverse events were prospectively recorded. Results: Among 5578 surgical patients, 1426 (25%) received Ketamine and 783 (55%) were included in the study (447 Ra-Ketamine, 339 S-Ketamine). Infusion strategy was similar in both groups. Patients in the Ra-Ketamine group had more hallucinations (1.4% vs 0%, risk difference of 1.34%, 95% confidence interval (CI) (−0.50 to 2.90), P=0.04) and received higher morphine doses in the PACU (10 mg inter-quartile range IQR 6–12 vs 8 mg 6–10; median difference 1.00 95% CI, 0.00–3.00; P=0.02). PACU length of stay was comparable in both groups (Ra-Ketamine: 105 min IQR 65–150 vs S-Ketamine: 100 min IQR 70–153, median difference −1.0 (95% CI, −10.0 to 6.0; P=0.70). Conclusions: S-Ketamine demonstrated a safer profile compared with Ra-Ketamine, including fewer psychodysleptic side effects and possible superior analgesic efficacy, supporting its potential to enhance the quality of perioperative care. Clinical trial registration: researchregistry11703

Read Full Paperexternally

Bookmark

View Full Paper

Cite This Study

Khoury et al. (Fri,) studied this question.

synapsesocial.com/papers/69fc2b608b49bacb8b3478bc https://doi.org/https://doi.org/10.1016/j.bjao.2026.100548

Bookmark

View Full Paper